Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference

November 8, 2012

ATLANTA, Nov. 8, 2012 /PRNewswire/ — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, President and Chief Executive Officer, will present at the Credit Suisse 2012 Healthcare Conference at 2:00 P.M. MST on Wednesday, November 14, 2012 in Phoenix, AZ.

The presentation will be webcast live and can be accessed on the Investor Relations section of the corporate website at http://www.alimerasciences.com. For those who are not available to listen to the live broadcast, the webcast will be archived for 30 days.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.

    ICR, LLC
    for Alimera Sciences
    John Mills
    310-954-1105
    John.Mills@icrinc.com

SOURCE Alimera Sciences, Inc.


Source: PR Newswire